New Perspectives in Radiological and Radiopharmaceutical Hybrid Imaging in Progressive Supranuclear Palsy: A Systematic Review

Strobel, Joachim; Müller, Hans-Peter; Ludolph, Albert C.; Beer, Ambros J.; Sollmann, Nico; Kassubek, Jan

doi:10.3390/cells12242776

Cited by 10Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

New Perspectives in Radiological and Radiopharmaceutical Hybrid Imaging in Progressive Supranuclear Palsy: A Systematic Review

Open access

Strobel, Joachim, Müller, Hans-Peter, Ludolph, Albert C., Beer, Ambros J., Sollmann, Nico, Kassubek, Jan·2023·Cells

DOI 10.3390/cells12242776PMC PMC10742083

Open this paper in CoChat — free account Open PDF

Abstract

Progressive supranuclear palsy (PSP) is a neurodegenerative disease characterized by four-repeat tau deposition in various cell types and anatomical regions, and can manifest as several clinical phenotypes, including the most common phenotype, Richardson’s syndrome. The limited availability of biomarkers for PSP relates to the overlap of clinical features with other neurodegenerative disorders, but identification of a growing number of biomarkers from imaging is underway. One way to increase the reliability of imaging biomarkers is to combine different modalities for multimodal imaging. This review aimed to provide an overview of the current state of PSP hybrid imaging by combinations of positron emission tomography (PET) and magnetic resonance imaging (MRI). Specifically, combined PET and MRI studies in PSP highlight the potential of [18F]AV-1451 to detect tau, but also the challenge in differentiating PSP from other neurodegenerative diseases. Studies over the last years showed a reduced synaptic density in [11C]UCB-J PET, linked [11C]PK11195 and [18F]AV-1451 markers to disease progression, and suggested the potential role of [18F]RO948 PET for identifying tau pathology in subcortical regions. The integration of quantitative global and regional gray matter analysis by MRI may further guide the assessment of reduced cortical thickness or volume alterations, and diffusion MRI could provide insight into microstructural changes and structural connectivity in PSP. Challenges in radiopharmaceutical biomarkers and hybrid imaging require further research targeting markers for comprehensive PSP diagnosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/cells12242776

Cites

158 of 158 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic radiopharmaceuticals offer valuable insights into organ function and disease presence.
“Lastly, diagnostic radiopharmaceuticals have gained prominence, offering valuable insights into organ function and disease presence [114].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [114]
The Methodological Overview for PET (section 3.1) says radiolabeled tracers reveal changes in brain metabolism, blood flow, and receptor density, and the Conclusions (section 5) call radiopharmaceutical biomarkers valuable for studying PSP. The claim extends those findings to organ function and disease presence generally; the Discussion (section 4) also cautions that these biomarkers may not provide sufficient diagnostic accuracy on their own. (LLM, conf=0.84)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

MR diffusion tensor spectroscopy and imaging
Basser, P. J., Mattiello, J., & LeBihan, D. (1994) · Biophysical Journal · doi:10.1016/s0006-3495(94)80775-1 · Cited by 5,970 · see citing works
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,374 · see citing works
Self-citation
Precision medicine, AI, and the future of personalized health care
Johnson, K. B., Wei, W., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., Zhao, J., & Snowdon, J. L. (2021) · Clinical and Translational Science · doi:10.1111/cts.12884 · Cited by 1,854 · see citing works
Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review
Assaf, Y., & Pasternak, O. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-0029-0 · Cited by 1,537 · see citing works
Diffusion tensor imaging and beyond
Tournier, J., Mori, S., & Leemans, A. (2011) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22924 · Cited by 921 · see citing works
Correction for partial volume effects in PET: principle and validation.
ROUSSET, O. G., Ma, Y., & Evans, A. C. (1998) · PubMed · Cited by 919 · see citing works
Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses
Panic, N., Leoncini, E., de Belvis, G., Ricciardi, W., & Boccia, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083138 · Cited by 883 · see citing works
Localization of Neurofibrillary Tangles and Beta-Amyloid Plaques in the Brains of Living Patients With Alzheimer Disease
Shoghi, K. I., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., Read, S., Satyamurthy, N., Petrič, A., Huang, S., et al. (2002) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200201000-00004 · Cited by 774 · see citing works
Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760 · see citing works
A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology
Erlandsson, K., Buvat, I., Pretorius, P. H., Thomas, B. A., & Hutton, B. F. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/21/r119 · Cited by 731 · see citing works
MRI-Based Attenuation Correction for PET/MRI: A Novel Approach Combining Pattern Recognition and Atlas Registration
Hofmann, M., Steinke, F., Scheel, V., Charpiat, G., Farquhar, J. D. R., Aschoff, P., Brady, M., Schölkopf, B., & Pichler, B. J. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.049353 · Cited by 495 · see citing works
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches
Boxer, A. L., Yu, J.-T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30157-6 · Cited by 485 · see citing works
Distribution patterns of tau pathology in progressive supranuclear palsy
Kovacs, G. G., Lukic, M. J., Irwin, D. J., Arzberger, T., Respondek, G., Lee, E. B., Coughlin, D., Giese, A., Grossman, M., Kurz, C., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02158-2 · Cited by 483 · see citing works
MR Imaging Index for Differentiation of Progressive Supranuclear Palsy from Parkinson Disease and the Parkinson Variant of Multiple System Atrophy
Quattrone, A., Nicoletti, G., Messina, D., Fera, F. S., Condino, F., Pugliese, P., Lanza, P. L., Barone, P., Morgante, L., Zappia, M., et al. (2007) · Radiology · doi:10.1148/radiol.2453061703 · Cited by 418 · see citing works
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease
Fodero‐Tavoletti, M. T., Okamura, N., Furumoto, S., Mulligan, R. S., Connor, A. R., McLean, C., Cao, D., Rigopoulos, A., Cartwright, G. A., O'Keefe, G. J., et al. (2011) · Brain · doi:10.1093/brain/awr038 · Cited by 329 · see citing works
How and how not to correct for CSF-contamination in diffusion MRI
Metzler-Baddeley, C., O'Sullivan, M. J., Bells, S., Pasternak, O., & Jones, D. K. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.08.043 · Cited by 291 · see citing works
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
Crișan, G., Moldovean-Cioroianu, N. S., Timaru, D.-G., Andrieș, G., Căinap, C., & Chiș, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095023 · Cited by 283 · see citing works
Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy
Brendel, M., Barthel, H., van Eimeren, T., MAREK, K. L., Beyer, L., Song, M., Palleis, C., Gehmeyr, M., Fietzek, U. M., Respondek, G., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2526 · Cited by 267 · see citing works
Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
Whitwell, J. L., Höglinger, G. U., Antonini, A., Bordelon, Y. M., Boxer, A. L., Colosimo, C., van Eimeren, T., Golbe, L. I., Kassubek, J., Kurz, C., et al. (2017) · Movement Disorders · doi:10.1002/mds.27038 · Cited by 261 · see citing works
Self-citation
In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18 F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls
Betthauser, T. J., Cody, K. A., Zammit, M. D., Murali, D., Converse, A. K., Barnhart, T. E., Stone, C. K., Rowley, H. A., Johnson, S. C., & Christian, B. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209650 · Cited by 260 · see citing works
Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy
Cope, T., Rittman, T., Borchert, R. J., Jones, P. S., Vatansever, D., Allinson, K. S. J., Passamonti, L., Rodríguez, P. V., Bevan-Jones, W. R., O'Brien, J. T., et al. (2017) · Brain · doi:10.1093/brain/awx347 · Cited by 240 · see citing works
Wave‐CAIPI for highly accelerated 3D imaging
Bilgiç, B., Gagoski, B. A., Cauley, S., Fan, A. P., Polimeni, J. R., Grant, P. E., Wald, L. L., & Setsompop, K. (2014) · Magnetic Resonance in Medicine · doi:10.1002/mrm.25347 · Cited by 232 · see citing works
Tauopathies.
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802395-2.00025-0 · Cited by 225 · see citing works
Cellular and pathological heterogeneity of primary tauopathies
Chung, D. C., Roemer, S. F., Petrucelli, L., & Dickson, D. W. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00476-x · Cited by 219 · see citing works
Free-water imaging in Parkinson’s disease and atypical parkinsonism
Planetta, P. J., Ofori, E., Pasternak, O., Burciu, R. G., Shukla, P., DeSimone, J. C., Okun, M. S., McFarland, N. R., & Vaillancourt, D. E. (2015) · Brain · doi:10.1093/brain/awv361 · Cited by 213 · see citing works
18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
Passamonti, L., Rodríguez, P. V., Hong, Y. T., Allinson, K. S. J., Williamson, D., Borchert, R. J., Sami, S. A. K., Cope, T., Bevan-Jones, W. R., Jones, P. S., et al. (2016) · Brain · doi:10.1093/brain/aww340 · Cited by 207 · see citing works
Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies
Kroth, H., Oden, F., Molette, J., Schieferstein, H., Capotosti, F., Mueller, A., Berndt, M., Schmitt-Willich, H., Darmency, V., Gabellieri, E., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04397-2 · Cited by 193 · see citing works
Abnormal metabolic networks in atypical parkinsonism
Eckert, T., Tang, C., Ma, Y., Brown, N., Lin, T. P., Frucht, S. J., Feigin, A., & Eidelberg, D. (2008) · Movement Disorders · doi:10.1002/mds.21933 · Cited by 191 · see citing works
Pathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies
Marquié, M., Normandin, M. D., Meltzer, A. C., Siao Tick Chong, M., Andrea, N. V., Antón‐Fernández, A., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24844 · Cited by 190 · see citing works
Recent developments on PET radiotracers for TSPO and their applications in neuroimaging
Zhang, L., Hu, K., Shao, T., Hou, L., Zhang, S., Ye, W., Josephson, L., Meyer, J. H., Zhang, M., Vasdev, N., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.006 · Cited by 187 · see citing works
In vivo quantification of neurofibrillary tangles with [18F]MK-6240
Pascoal, T. A., Shin, M., Kang, M. S., Chamoun, M., Chartrand, D. A., Mathotaarachchi, S. S., Bennacef, I., Therriault, J., Ng, K. P., Hopewell, R., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0402-y · Cited by 185 · see citing works
The development and validation of tau PET tracers: current status and future directions
Okamura, N., Harada, R., Ishiki, A., Kikuchi, A., Nakamura, T., & Kudo, Y. (2018) · Clinical and Translational Imaging · doi:10.1007/s40336-018-0290-y · Cited by 183 · see citing works
Discovery of 6-(Fluoro- 18 F )-3-(1 H -pyrrolo[2,3- c ]pyridin-1-yl)isoquinolin-5-amine ([ 18 F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)
Walji, A. M., Hostetler, E. D., Selnick, H. G., Zeng, Z., Miller, P. J., Bennacef, I., Salinas, C. A., Connolly, B., Gantert, L. T., Holahan, M. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00166 · Cited by 181 · see citing works
18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases
Soleimani‐Meigooni, D. N., Iaccarino, L., Joie, R. L., Baker, S. L., Bourakova, V., Boxer, A. L., Edwards, L., Eser, R. A., Gorno‐Tempini, M., Jagust, W. J., et al. (2020) · Brain · doi:10.1093/brain/awaa276 · Cited by 178 · see citing works
18F‐flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study
Schonhaut, D. R., McMillan, C. T., Spina, S., Dickerson, B. C., Siderowf, A., Devous, M. D., Tsai, R., Winer, J., Russell, D. S., Litvan, I., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25060 · Cited by 175 · see citing works
The physical and biological basis of quantitative parameters derived from diffusion MRI.
Winston, G. P. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2223-4292.2012.12.05 · Cited by 174 · see citing works
Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease
Harada, R., Ishiki, A., Kai, H., Sato, N., Furukawa, K., Furumoto, S., Tago, T., Tomita, N., Watanuki, S., Hiraoka, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197426 · Cited by 168 · see citing works
Early differential diagnosis of Parkinson's disease with 18 F‐fluorodeoxyglucose and positron emission tomography
Eidelberg, D., Moeller, J. R., Ishikawa, T., DHAWAN, V. M., Spetsieris, P. G., Chaly, T., Belakhlef, A., Mandel, F. S., Przedborski, S., & Fahn, S. (1995) · Neurology · doi:10.1212/wnl.45.11.1995 · Cited by 163 · see citing works
Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET
Ossenkoppele, R., Tolboom, N., Foster‐Dingley, J. C., Adriaanse, S. F., Boellaard, R., Yaqub, M. M., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2102-3 · Cited by 161 · see citing works
[18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy
Whitwell, J. L., Lowe, V. J., Tosakulwong, N., Weigand, S. D., Senjem, M. L., Schwarz, C. G., Spychalla, A. J., Petersen, R. C., Jack, C. R., & Josephs, K. A. (2017) · Movement Disorders · doi:10.1002/mds.26834 · Cited by 159 · see citing works
A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease
Quattrone, A., Morelli, M., Nigro, S. L., Quattrone, A., Vescio, B., Arabia, G., Nicoletti, G., Nisticò, R., Salsone, M., Novellino, F., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.07.016 · Cited by 158 · see citing works
Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy
Ali, F., Martin, P. R., Botha, H., Ahlskog, J. E., Bower, J. H., Masumoto, J. Y., Maraganore, D. M., Hassan, A., Eggers, S. D. Z., Boeve, B. F., et al. (2019) · Movement Disorders · doi:10.1002/mds.27619 · Cited by 157 · see citing works
Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes
Saeed, U., Lang, A. E., & Masellis, M. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.572976 · Cited by 153 · see citing works
PET Imaging of Neuroinflammation in Alzheimer’s Disease
Zhou, R., Ji, B., Kong, Y., Qin, L., Ren, W., Guan, Y., & Ni, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.739130 · Cited by 150 · see citing works
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies
Stamelou, M., Respondek, G., Giagkou, N., Whitwell, J. L., Kovács, G. G., & Höglinger, G. U. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00541-5 · Cited by 143 · see citing works
An introduction to PET and SPECT neuroreceptor quantification models.
Ichise, M., Meyer, J. H., & Yonekura, Y. (2001) · PubMed · Cited by 130 · see citing works
Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
Chiotis, K., Saint‐Aubert, L., Savitcheva, I., Jelić, V., Andersen, P., Jonasson, M., Eriksson, J., Lubberink, M., Almkvist, O., Wall, A. E., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3363-z · Cited by 127 · see citing works
18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
Passamonti, L., Vázquez Rodríguez, P., Hong, Y. T., et al. (2017) · Apollo (University of Cambridge) · doi:10.17863/cam.7964 · Cited by 125 · see citing works
Advanced diffusion MRI fiber tracking in neurosurgical and neurodegenerative disorders and neuroanatomical studies: A review
Abhinav, K., Yeh, F.-C. F., Pathak, S., Suski, V. R., Lacomis, D., Friedlander, R. M., & Fernandez-Miranda, J. C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.08.002 · Cited by 119 · see citing works
[ 11 C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy
Passamonti, L., Rodríguez, P. V., Hong, Y. T., Allinson, K. S. J., Bevan-Jones, W. R., Williamson, D., Jones, P. S., Arnold, R., Borchert, R. J., Surendranathan, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005610 · Cited by 115 · see citing works
Motion Correction Options in PET/MRI
Catana, C. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.01.001 · Cited by 114 · see citing works
Progressive supranuclear palsy: Advances in diagnosis and management
Coughlin, D. G., & Litvan, I. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.04.014 · Cited by 113 · see citing works
Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages
Pascoal, T. A., Benedet, A. L., Tudorascu, D., Therriault, J., Mathotaarachchi, S. S., Savard, M., Lussier, F. Z., Tissot, C., Chamoun, M., Kang, M. S., et al. (2021) · Brain · doi:10.1093/brain/awab248 · Cited by 113 · see citing works
Tau deposition patterns are associated with functional connectivity in primary tauopathies
Franzmeier, N., Brendel, M., Beyer, L., Slemann, L., Kovács, G. G., Arzberger, T., Kurz, C., Respondek, G., Ječmenica‐Lukić, M., Biel, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28896-3 · Cited by 112 · see citing works
Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
Jie, C. V. M. L., Treyer, V., Schibli, R., & Mu, L. (2021) · Pharmaceuticals · doi:10.3390/ph14020110 · Cited by 111 · see citing works
Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia
Chiotis, K., Saint‐Aubert, L., Rodriguez‐Vieitez, E., Leuzy, A., Almkvist, O., Savitcheva, I., Jonasson, M., Lubberink, M., Wall, A., Antoni, G., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.108 · Cited by 107 · see citing works
PET Imaging of Neuropathology in Tauopathies: Progressive Supranuclear Palsy
Kepe, V., Bordelon, Y., Boxer, A., Huang, S.-C., Liu, J., Thiede, F. C., Mazziotta, J. C., Mendez, M. F., Donoghue, N., Small, G. W., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130032 · Cited by 106 · see citing works
PET Radiopharmaceuticals for Alzheimer’s Disease and Parkinson’s Disease Diagnosis, the Current and Future Landscape
Uzuegbunam, B. C., Librizzi, D., & Yousefi, B. H. (2020) · Molecules · doi:10.3390/molecules25040977 · Cited by 103 · see citing works
Clinical Utility of 18F‐APN ‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy
Li, L., Liu, F., Li, M., Lu, J., Sun, Y., Liang, X., Bao, W., Chen, Q.-S., Li, X., Zhou, X., et al. (2021) · Movement Disorders · doi:10.1002/mds.28672 · Cited by 98 · see citing works
Direct Comparison of the Tau PET Tracers18F-Flortaucipir and18F-MK-6240 in Human Subjects
Gogola, A., Minhas, D. S., Villemagne, V. L., Cohen, A. D., Mountz, J. M., Pascoal, T. A., Laymon, C. M., Mason, N. S., Ikonomović, M. D., Mathis, C. A., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.254961 · Cited by 97 · see citing works
In vivo tau imaging: Obstacles and progress
Villemagne, V. L., & Okamura, N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.013 · Cited by 96 · see citing works
Synaptic Loss in Primary Tauopathies Revealed by [ <scp> 11 C </scp> ] <scp>UCB‐J</scp> Positron Emission Tomography
Holland, N., Jones, P. S., Savulich, G., Wiggins, J. K., Hong, Y. T., Fryer, T. D., Manavaki, R., Sephton, S. M., Boros, I., Malpetti, M., et al. (2020) · Movement Disorders · doi:10.1002/mds.28188 · Cited by 93 · see citing works
Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants
Whitwell, J. L., Tosakulwong, N., Botha, H., Ali, F., Clark, H. M., Duffy, J. R., Utianski, R. L., Stevens, C. A., Weigand, S. D., Schwarz, C. G., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.102152 · Cited by 92 · see citing works
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
Leuzy, A., Pascoal, T. A., Strandberg, O. T., Insel, P. S., Smith, R. A., Mattsson, N., Benedet, A. L., Cho, H., Lyoo, C. H., Joie, R. L., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05401-4 · Cited by 86 · see citing works
Diffusion-Weighted Imaging: Recent Advances and Applications.
Martínez-Heras, E., Grussu, F., Prados, F., Solana, E., & Llufriu, S. (2021) · Seminars in ultrasound, CT, and MR · doi:10.1053/j.sult.2021.07.006 · Cited by 86 · see citing works
Neuroinflammation predicts disease progression in progressive supranuclear palsy
Malpetti, M., Passamonti, L., Jones, P. S., Street, D., Rittman, T., Fryer, T. D., Hong, Y. T., Vàsquez Rodriguez, P., Bevan-Jones, W. R., Aigbirhio, F. I., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325549 · Cited by 85 · see citing works
Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy
Malpetti, M., Passamonti, L., Rittman, T., Jones, P. S., Vázquez Rodríguez, P., Bevan‐Jones, W. R., Hong, Y. T., Fryer, T. D., Aigbirhio, F. I., O'Brien, J. T., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25911 · Cited by 83 · see citing works
Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging
Murugan, N., Chiotis, K., Rodriguez-Vieitez, E., Lemoine, L., Ågren, H., & Nordberg, A. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04305-8 · Cited by 82 · see citing works
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care
Bluett, B., Pantelyat, A. Y., Litvan, I., Ali, F., Apetauerova, D., Bega, D., Bloom, L., Bower, J. H., Boxer, A. L., Dale, M. L., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.694872 · Cited by 82 · see citing works
Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies
Fodero‐Tavoletti, M. T., Furumoto, S., Taylor, L. S., McLean, C., Mulligan, R. S., Birchall, I. E., Harada, R., Masters, C. L., Yanai, K., Kudo, Y., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt240 · Cited by 73 · see citing works
[18F]‐THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy
Brendel, M., Schönecker, S., Höglinger, G., Lindner, S., Havla, J., Blautzik, J., Sauerbeck, J., Rohrer, G., Zach, C., Vettermann, F., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00440 · Cited by 72 · see citing works
TSPO imaging in animal models of brain diseases
Camp, N. V., Lavisse, S., Roost, P., Gubinelli, F., Hillmer, A. T., & Boutin, H. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05379-z · Cited by 71 · see citing works
From simultaneous to synergistic MR‐PET brain imaging: A review of hybrid MR‐PET imaging methodologies
Chen, Z., Jamadar, S. D., Li, S., Sforazzini, F., Baran, J., Ferris, N. J., Shah, N. J., & Egan, G. F. (2018) · Human Brain Mapping · doi:10.1002/hbm.24314 · Cited by 67 · see citing works
Cortical Synapse Loss in progressive Supranuclear palsy
Bigio, E. H., Vono, M. B., Satumtira, S., Adamson, J. L., Sontag, E., Hynan, L. S., White, C. L., Baker, M. C., & Hutton, M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.5.403 · Cited by 65 · see citing works
Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy
Ishiki, A., Harada, R., Kai, H., Sato, N., Totsune, T., Tomita, N., Watanuki, S., Hiraoka, K., Ishikawa, Y., Funaki, Y., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0556-7 · Cited by 61 · see citing works
In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317
Betthauser, T. J., Lao, P. J., Murali, D., Barnhart, T. E., Furumoto, S., Okamura, N., Stone, C. K., Johnson, S. C., & Christian, B. T. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.182980 · Cited by 60 · see citing works
Sensitivity–Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration
Ghirelli, A., Tosakulwong, N., Weigand, S. D., Clark, H. M., Ali, F., Botha, H., Duffy, J. R., Utianski, R. L., Buciuc, M., Murray, M. E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25893 · Cited by 59 · see citing works
PET/MRI: Technical Challenges and Recent Advances
Jung, J. H., Choi, Y., & Im, K. C. (2016) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-016-0393-1 · Cited by 55 · see citing works
Positron emission tomography imaging of tau pathology in progressive supranuclear palsy
Coakeley, S., Cho, S. S., Koshimori, Y., Rusjan, P., Harris, M., Ghadery, C., Kim, J., Lang, A. E., Wilson, A. A., Houle, S., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16683695 · Cited by 55 · see citing works
Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study
Nigro, S. L., Antonini, A., Vaillancourt, D. E., Seppi, K., Ceravolo, R., Strafella, A. P., Augimeri, A., Quattrone, A., Morelli, M., Weis, L., et al. (2020) · Movement Disorders · doi:10.1002/mds.28007 · Cited by 55 · see citing works
Four-Repeat Tauopathies: Current Management and Future Treatments
VandeVrede, L. A., Ljubenkov, P. A., Rojas, J. C., Welch, A. E., & Boxer, A. L. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00888-5 · Cited by 53 · see citing works
The utility of FDG-PET in the differential diagnosis of Parkinsonism
Brajković, L., Kostić, V., Sobic-Saranovic, D. P., Stefanova, E. D., Ječmenica‐Lukić, M., Jesic, A., Stojiljković, M., Odalović, S., Gallivanone, F., Castiglioni, I., et al. (2017) · Neurological Research · doi:10.1080/01616412.2017.1312211 · Cited by 49 · see citing works
MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy
Whitwell, J. L., Tosakulwong, N., Schwarz, C. G., Botha, H., Senjem, M. L., Spychalla, A. J., Ahlskog, J. E., Knopman, D. S., Petersen, R. C., Jack, C. R., et al. (2018) · Movement Disorders · doi:10.1002/mds.27546 · Cited by 49 · see citing works
In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy
Endo, H., Shimada, H., Sahara, N., Ono, M., Koga, S., Kitamura, S., Niwa, F., Hirano, S., Kimura, Y., Ichise, M., et al. (2019) · Movement Disorders · doi:10.1002/mds.27643 · Cited by 49 · see citing works
Radiosynthesis, In Vitro and In Vivo Evaluation of [18F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies
Lindberg, A., Knight, A. C., Sohn, D., Rákos, L., Tong, J., Radelet, A., Mason, N. S., Stehouwer, J. S., Lopresti, B. J., Klunk, W. E., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00801 · Cited by 49 · see citing works
Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy‐Parkinsonism From Parkinson's Disease
Quattrone, A., Bianco, M. G., Antonini, A., Vaillancourt, D. E., Seppi, K., Ceravolo, R., Strafella, A. P., Tedeschi, G., Tessitore, A., Cilia, R., et al. (2022) · Movement Disorders · doi:10.1002/mds.28992 · Cited by 49 · see citing works
Attenuation correction for human PET/MRI studies
Catana, C. (2020) · Physics in Medicine and Biology · doi:10.1088/1361-6560/abb0f8 · Cited by 47 · see citing works
Differential diagnosis of parkinsonism based on deep metabolic imaging indices
Wu, P., Zhao, Y. S., Wu, J., Brendel, M., Lu, J., Ge, J., Bernhardt, A. M., Li, L., Alberts, I., Katzdobler, S., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263029 · Cited by 46 · see citing works
MR Imaging–Guided Partial Volume Correction of PET Data in PET/MR Imaging
Erlandsson, K., Dickson, J. C., Arridge, S., Atkinson, D., Sebastien Ourselin, A., & Hutton, B. F. (2015) · PET Clinics · doi:10.1016/j.cpet.2015.09.002 · Cited by 45 · see citing works
Correction for Partial Volume Effect Is a Must, Not a Luxury, to Fully Exploit the Potential of Quantitative PET Imaging in Clinical Oncology
Alavi, A. A., Werner, T. J., Høilund‐Carlsen, P. F., & Zaidi, H. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1146-y · Cited by 45 · see citing works
Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies
Chauveau, F., Becker, G., & Boutin, H. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05425-w · Cited by 45 · see citing works
Partial volume effect in SPECT & PET imaging and impact on radionuclide dosimetry estimates.
Marquis, H., Willowson, K. P., & Bailey, D. L. (2023) · PubMed · doi:10.22038/aojnmb.2022.63827.1448 · Cited by 43 · see citing works
[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP
Coakeley, S., Cho, S. S., Koshimori, Y., Rusjan, P., Ghadery, C., Kim, J., Lang, A. E., Houle, S., & Strafella, A. P. (2017) · Brain Structure and Function · doi:10.1007/s00429-017-1507-y · Cited by 42 · see citing works
MRI-Driven PET Image Optimization for Neurological Applications
Zhu, Y., & Zhu, X. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00782 · Cited by 42 · see citing works
Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson’s Disease1
Buongiorno, M., Antonelli, F., Compta, Y., Fernandez, Y., Pavı́a, J., Lomeña, F., Ríos, J., Ramírez, I., García, J. R., Soler, M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160698 · Cited by 39 · see citing works
Differentiation of atypical Parkinson syndromes
Höglinger, G. U., Kassubek, J., Csóti, I., Ehret, R., Herbst, H., Wellach, I., Winkler, J., & Jost, W. H. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1700-4 · Cited by 39 · see citing works
Self-citation
Magnetic Resonance Imaging of the Brain Using Compressed Sensing – Quality Assessment in Daily Clinical Routine
Mönch, S., Sollmann, N., Hock, A., Zimmer, C., Kirschke, J. S., & Hedderich, D. M. (2019) · Clinical Neuroradiology · doi:10.1007/s00062-019-00789-x · Cited by 39 · see citing works
Self-citation
Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study
Holland, N., Malpetti, M., Rittman, T., Mak, E. E., Passamonti, L., Kaalund, S. S., Hezemans, F. H., Jones, P. S., Savulich, G., Hong, Y. T., et al. (2022) · Brain · doi:10.1093/brain/awab282 · Cited by 39 · see citing works
Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer's disease: A combined positron emission tomography/magnetic resonance imaging study
Sone, D., Imabayashi, E., Maikusa, N., Okamura, N., Furumoto, S., Kudo, Y., Ogawa, M., Takano, H., Yokoi, Y., Sakata, M., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.07.001 · Cited by 38 · see citing works
Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy
Whitwell, J. L., Ahlskog, J. E., Tosakulwong, N., Senjem, M. L., Spychalla, A. J., Petersen, R. C., Jack, C. R., Lowe, V. J., & Josephs, K. A. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.12.016 · Cited by 38 · see citing works
In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies
Mak, E., Holland, N., Jones, P. S., Savulich, G., Low, A., Malpetti, M., Kaalund, S. S., Passamonti, L., Rittman, T., Romero-García, R., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.01.016 · Cited by 38 · see citing works
Positron emission tomography imaging of the γ-aminobutyric acid system
Andersson, J. D., Matuskey, D., & Finnema, S. J. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.08.010 · Cited by 37 · see citing works
Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease
Lu, Y., Toyonaga, T., Naganawa, M., Gallezot, J., Chen, M.-K., Mecca, A. P., van Dyck, C. H., & Carson, R. E. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118248 · Cited by 37 · see citing works
The evolution of parkinsonism in primary progressive apraxia of speech: a 6-year longitudinal study
Seckin, Z. I., Duffy, J. R., Strand, E. A., Clark, H. M., Utianski, R. L., Machulda, M. M., Botha, H., Ali, F., Thu Pham, N. T., Lowe, V. J., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.09.039 · Cited by 36 · see citing works
Characterization of 18F-PM-PBB3 (18F-APN-1607) Uptake in the rTg4510 Mouse Model of Tauopathy
Weng, C.-C., Hsiao, I.-T., Yang, Q.-F., Yao, C.-H., Tai, C., Wu, M., Yen, T., Jang, M., & Lin, K.-J. (2020) · Molecules · doi:10.3390/molecules25071750 · Cited by 35 · see citing works
18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy
Messerschmidt, K., Barthel, H., Brendel, M., Scherlach, C., Hoffmann, K., Rauchmann, B., Rullmann, M., MAREK, K. L., Villemagne, V. L., Rumpf, J., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262854 · Cited by 35 · see citing works
18F-FDG PET Is an Early Predictor of Overall Survival in Suspected Atypical Parkinsonism
Hellwig, S., Frings, L., Amtage, F., Buchert, R., Spehl, T. S., Rijntjes, M., Tüscher, O., Weiller, C., Weber, W., Vach, W., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.159822 · Cited by 34 · see citing works
An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability
Kurz, C., Ebersbach, G., Respondek, G., Giese, A., Arzberger, T., & Höglinger, G. U. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0391-7 · Cited by 33 · see citing works
Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
Katzdobler, S., Nitschmann, A., Barthel, H., Bischof, G. N., Beyer, L., MAREK, K. L., Song, M., Wagemann, O., Palleis, C., Weidinger, E., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05964-w · Cited by 33 · see citing works
Multimodal neuroimaging relationships in progressive supranuclear palsy
Sintini, I., Schwarz, C. G., Senjem, M. L., Reid, R. I., Botha, H., Ali, F., Ahlskog, J. E., Jack, C. R., Lowe, V. J., Josephs, K. A., et al. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.07.001 · Cited by 32 · see citing works
18F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy
Nicastro, N., Rodríguez, P. V., Malpetti, M., Bevan-Jones, W. R., Jones, P. S., Passamonti, L., Aigbirhio, F. I., O'Brien, J. T., & Rowe, J. B. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09566-9 · Cited by 32 · see citing works
Exploring the Acceleration Limits of Deep Learning Variational Network–based Two-dimensional Brain MRI
Radmanesh, A., Muckley, M. J., Murrell, T., Lindsey, E., Sriram, A., Knöll, F., Sodickson, D. K., & Lui, Y. W. (2022) · Radiology Artificial Intelligence · doi:10.1148/ryai.210313 · Cited by 32 · see citing works
Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System Atrophy
Greene, P. E. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000751 · Cited by 30 · see citing works
Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease
Rullmann, M., Brendel, M., Schroeter, M. L., Saur, D., Levin, J., Perneczky, R. G., Tiepolt, S., Patt, M., Mueller, A., Villemagne, V. L., et al. (2022) · Biomolecules · doi:10.3390/biom12030458 · Cited by 29 · see citing works
Epidemiology of Progressive Supranuclear Palsy: Real World Data from the Second Largest Health Plan in Israel
Barer, Y., Chodick, G., Cohen, R., Grabarnik‐John, M., Ye, X., Zamudio, J., & Gurevich, T. (2022) · Brain Sciences · doi:10.3390/brainsci12091126 · Cited by 29 · see citing works
An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with 18F-PM-PBB3 (18F-APN-1607)
Tagai, K., Ikoma, Y., Endo, H., Debnath, O. B., Seki, C., Matsuoka, K., Matsumoto, H., Oya, M., Hirata, K., Shinotoh, H., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119763 · Cited by 28 · see citing works
The Sensitivity of Tau Tracers for the Discrimination of Alzheimer’s Disease Patients and Healthy Controls by PET
Mohammadi, Z., Alizadeh, H., Marton, J., & Cumming, P. D. (2023) · Biomolecules · doi:10.3390/biom13020290 · Cited by 28 · see citing works
The diagnosis of progressive supranuclear palsy: current opinions and challenges
Ali, F., & Josephs, K. A. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1489241 · Cited by 27 · see citing works
Corticobasal degeneration: advances in clinicopathology and biomarkers
Svenningsson, P. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000707 · Cited by 26 · see citing works
Highly accelerated time-of-flight magnetic resonance angiography using spiral imaging improves conspicuity of intracranial arterial branches while reducing scan time
Greve, T., Sollmann, N., Hock, A., Hey, S., Gnanaprakasam, V., Nijenhuis, M., Zimmer, C., & Kirschke, J. S. (2019) · European Radiology · doi:10.1007/s00330-019-06442-y · Cited by 26 · see citing works
Self-citation
Diffusion tensor imaging analysis in three progressive supranuclear palsy variants
Whitwell, J. L., Tosakulwong, N., Clark, H. M., Ali, F., Botha, H., Weigand, S. D., Sintini, I., Machulda, M. M., Schwarz, C. G., Reid, R. I., et al. (2021) · Journal of Neurology · doi:10.1007/s00415-020-10360-1 · Cited by 26 · see citing works
Longitudinal Synaptic Loss in Primary Tauopathies: An In Vivo [ 11 C ] UCB‐J Positron Emission Tomography Study
Holland, N., Jones, P. S., Savulich, G., Naessens, M., Malpetti, M., Whiteside, D. J., Street, D., Swann, P., Hong, Y. T., Fryer, T. D., et al. (2023) · Movement Disorders · doi:10.1002/mds.29421 · Cited by 25 · see citing works
PET/MRI, Part 2: Technologic Principles
Currie, G. M., Kamvosoulis, P., & Bushong, S. C. (2021) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.120.261862 · Cited by 24 · see citing works
Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective
Ricci, M., Cimini, A., Camedda, R., Chiaravalloti, A., & Schillaci, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313002 · Cited by 24 · see citing works
Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology
Brendel, M., Yousefi, B. H., Blume, T., Herz, M., Focke, C., Deußing, M., Peters, F., Lindner, S., von Ungern‐Sternberg, B., Drzezga, A. E., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00174 · Cited by 23 · see citing works
MRI-based neuroimaging: atypical parkinsonisms and other movement disorders
Kassubek, J. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000578 · Cited by 20 · see citing works
Self-citation
Hybrid PET/MRI Methodology
Aiello, M., Cavaliere, C., Marchitelli, R., d'Albore, A., Vita, E. D., & Salvatore, M. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.026 · Cited by 20 · see citing works
Clinical, MRI and 18F-FDG-PET/CT analysis of progressive supranuclear palsy
Zhao, P., Zhang, B., Gao, S., & Li, X. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.06.008 · Cited by 20 · see citing works
Disease course and treatment patterns in progressive supranuclear palsy: A real-world study
Morgan, J. C., Ye, X., Mellor-Bowman, J., Golden, K. J., Zamudio, J., Chiodo, L. A., Bao, Y., & Xie, T. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117293 · Cited by 20 · see citing works
PI-2620 Lead Optimization Highlights the Importance of Off-Target Assays to Develop a PET Tracer for the Detection of Pathological Aggregated Tau in Alzheimer’s Disease and Other Tauopathies
Kroth, H., Oden, F., Molette, J., Schieferstein, H., Gabellieri, E., Mueller, A., Berndt, M., Sreenivasachary, N., Serra, A. M., Capotosti, F., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00861 · Cited by 20 · see citing works
Imaging pathological tau in atypical parkinsonisms: A review
Mena, A. M., & Strafella, A. P. (2022) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2022.100155 · Cited by 20 · see citing works
Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [18F]PI-2620 PET/MRI study
Aghakhanyan, G., Rullmann, M., Rumpf, J., Schroeter, M. L., Scherlach, C., Patt, M., Brendel, M., Koglin, N., Stephens, A. W., Claßen, J., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05952-0 · Cited by 19 · see citing works
Differences in Striatal Metabolism in [18F]FDG PET in Parkinson’s Disease and Atypical Parkinsonism
Seiffert, A. P., Gómez‐Grande, A., Alonso-Gómez, L., Méndez-Guerrero, A., Villarejo‐Galende, A., Aguilera, E. J. G., & González, P. S. (2022) · Diagnostics · doi:10.3390/diagnostics13010006 · Cited by 19 · see citing works
Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies
Choi, Y., Ha, S., Lee, Y., Kim, Y. K., Lee, D. S., & Kim, D. J. (2017) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-017-0484-7 · Cited by 18 · see citing works
Hybrid PET-MRI Applications in Movement Disorders
Tondo, G., Esposito, M., Dervenoulas, G., Wilson, H., Politis, M., & Pagano, G. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.10.003 · Cited by 18 · see citing works
Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome
Schröter, N., Blazhenets, G., Frings, L., Barkhausen, C., Jost, W. H., Weiller, C., Rijntjes, M., & Meyer, P. T. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002949 · Cited by 18 · see citing works
Spatial attention and spatial short term memory in PSP and Parkinson's disease
Smith, D. T., Casteau, S., & Archibald, N. K. (2021) · Cortex · doi:10.1016/j.cortex.2020.12.019 · Cited by 18 · see citing works
Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy
Matsuoka, K., Takado, Y., Tagai, K., Kubota, M., Sano, Y., Takahata, K., Ono, M., Seki, C., Matsumoto, H., Endo, H., et al. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120514 · Cited by 18 · see citing works
Pitfalls on PET/MRI
Afaq, A., Faul, D. D., Chebrolu, V. V., Wan, S., Hope, T. A., Haibach, P. V., & Bomanji, J. B. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2021.04.003 · Cited by 17 · see citing works
Imaging tau pathology in Parkinsonisms
Coakeley, S., & Strafella, A. P. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-017-0023-3 · Cited by 15 · see citing works
Novel Ultrafast Spiral Head MR Angiography Compared to Standard MR and CT Angiography
Greve, T., Sollmann, N., Hock, A., Zimmer, C., & Kirschke, J. S. (2020) · Journal of Neuroimaging · doi:10.1111/jon.12791 · Cited by 15 · see citing works
Self-citation
Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy
Hauer, K. O., Pawlik, D., Leuzy, A., Janelidze, S., Hall, S., Hansson, O., & Smith, R. A. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.11.018 · Cited by 15 · see citing works
Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [18F]-PI-2620 tau-PET signal
Schönecker, S., Palleis, C., Franzmeier, N., Katzdobler, S., Ferschmann, C., Schuster, S., Finze, A., Scheifele, M., Prix, C., Fietzek, U. M., et al. (2023) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103402 · Cited by 15 · see citing works
Automatic covariance pattern analysis outperforms visual reading of 18F‐fluorodeoxyglucose‐positron emission tomography ( FDG‐PET) in variant progressive supranuclear palsy
Buchert, R., Wegner, F., Huppertz, H., Berding, G., Brendel, M., Apostolova, I. I., Buhmann, C., Dierks, A., Katzdobler, S., Klietz, M., et al. (2023) · Movement Disorders · doi:10.1002/mds.29581 · Cited by 14 · see citing works
The comorbidity and co-medication profile of patients with progressive supranuclear palsy
Greten, S., Wegner, F., Jensen, I., Krey, L., Rogozinski, S., Fehring, M., Heine, J., Doll‐Lee, J., Pötter‐Nerger, M., Zeitzschel, M., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12006-4 · Cited by 14 · see citing works
Self-citation
In Vivo 18F‐APN ‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings
Zhou, X., Lu, J., Liu, F., Wu, P., Zhao, J., Ju, Z., Tang, Y., Shi, Q., Lin, H., Wu, J., et al. (2021) · Movement Disorders · doi:10.1002/mds.28867 · Cited by 13 · see citing works
Progressive supranuclear palsy misdiagnosed as Parkinson′s disease: A case report and review of literature
Owolabi, L. (2013) · Annals of Medical and Health Sciences Research · doi:10.4103/2141-9248.121221 · Cited by 12 · see citing works
A case of progressive supranuclear palsy with predominant cerebellar ataxia diagnosed by [18F]PM-PBB3 tau PET
Ishizuchi, K., Takizawa, T., Tezuka, T., Takahata, K., Seki, M., Tabuchi, H., Ueda, R., Kubota, M., Mimura, M., Nakahara, J., et al. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117440 · Cited by 12 · see citing works
Diagnostic accuracy of cerebral [18F]FDG PET in atypical parkinsonism
Houssein, N. J., Henriksen, A. C., Hejl, A., & Marner, L. (2023) · EJNMMI Research · doi:10.1186/s13550-023-01025-x · Cited by 12 · see citing works
PET-CT and PET-MRI in Neurology
Ciarmiello, A., & Mansi, L. (2016) · Springer eBooks · doi:10.1007/978-3-319-31614-7 · Cited by 11 · see citing works
[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
Santillo, A. F., Leuzy, A., Honer, M., Waldö, M. L., Tideman, P., Harper, L., Ohlsson, T. G., Moes, S., Giannini, L., Jögi, J., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06065-4 · Cited by 10 · see citing works
Brain FDG-PET correlates of saccadic disorders in early PSP
Pin, G., Labouré, J., Guedj, É., Félician, O., Grimaldi, S., Azulay, J., Ceccaldi, M. P., & Koric, L. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11824-w · Cited by 10 · see citing works
Evaluation of Deep Learning–Based Approaches to Segment Bowel Air Pockets and Generate Pelvic Attenuation Maps from CAIPIRINHA-Accelerated Dixon MR Images
Sari, H., Reaungamornrat, J., Catalano, O. A., Vera-Olmos, J., Izquierdo‐Garcia, D., Morales, M. A., Torrado-Carvajal, Á., Ng, T. S. C., Malpica, N., Kamen, A., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.261032 · Cited by 9 · see citing works
A case of tauopathy with auditory agnosia and dysprosody diagnosed by [18F]PM-PBB3 tau PET scan
Mashima, K., Konishi, M., Tezuka, T., Ito, D., & Mimura, M. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05287-y · Cited by 7 · see citing works
[P3–378]: FIRST‐IN‐HUMAN PET STUDY WITH 18F‐AM‐PBB3 AND 18F‐PM‐PBB3
Shimada, H., Kitamura, S., Ono, M., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.1594 · Cited by 6 · see citing works
PVE correction in PET from PVE affected images
Gallivanone, F., Stefano, A., Canevari, C., Messa, C., Gilardi, M. C., & Castiglioni, I. (2009) · IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC) · doi:10.1109/nssmic.2009.5401688 · Cited by 2 · see citing works
High‐yield synthesis of a tau PET radioligand and its nonradioactive ligand using an alternative protection and deprotection strategy
Kim, H., & Choe, Y. S. (2020) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3894 · Cited by 2 · see citing works
Progressive supranuclear palsy’s economical burden: the use and costs of healthcare resources in a large health provider in Israel
Barer, Y., Cohen, R., Grabarnik‐John, M., Ye, X., Zamudio, J., Gurevich, T., & Chodick, G. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11714-1 · Cited by 1 · see citing works

Flagged first, then by citations

1 of the 159 references couldn’t be matched to a known paper.

Sorted by citations

Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144 · see citing works
“Lastly, diagnostic radiopharmaceuticals have gained prominence, offering valuable insights into organ function and disease presence [114].”
Background
Clinical and neuroimaging characteristics of primary lateral sclerosis with overlapping features of progressive supranuclear palsy
Badihian, N., Gatto, R. G., Satoh, R., Ali, F., Clark, H. M., Pham, N. T. T., Whitwell, J. L., & Josephs, K. A. (2024) · European Journal of Neurology · doi:10.1111/ene.16320 · Cited by 11 · see citing works
Advances in radiopharmaceuticals for precision medicine: A global and Chinese perspective
Huang, Q., & Huang, G. (2024) · LabMed discovery. · doi:10.1016/j.lmd.2024.100031 · Cited by 10 · see citing works
Possible Impact of Peripheral Inflammatory Factors and Interleukin-1β (IL-1β) on Cognitive Functioning in Progressive Supranuclear Palsy–Richardson Syndrome (PSP-RS) and Progressive Supranuclear Palsy–Predominant Parkinsonism (PSP-P)
Chunowski, P., Otto‐Ślusarczyk, D., Duszyńska-Wąs, K., Drzewińska, A., Załęski, A., Madetko‐Alster, N., Wiercińska‐Drapało, A., Struga, M., & Alster, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313211 · Cited by 9 · see citing works
GV1001 reduces pathological 4R tau and functional deficits in models relevant to progressive supranuclear palsy
Jang, K.-B., Kang, D., Lee, M.-H., Lukianenko, N., Kim, Y. K., Lim, S., Kim, S., & Cho, H. J. (2026) · Scientific Reports · doi:10.1038/s41598-026-42195-7 · Cited by 1 · see citing works
Retinal optical coherence tomography changes as biomarkers for Parkinsonism duration and severity in the Kashmiri population
Mohammad, I., Rashid, S., Sanie, B., Ashraf, S., & Raina, A. (2024) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_27_24
Misdiagnosis of Frontotemporal Dementia in a Patient With Progressive Supranuclear Palsy: A Case Report and Volumetric Neuroimaging Application
Eguiguren, C. B., Vera, M. D. F., & Diaz, A. (2025) · Cureus · doi:10.7759/cureus.81421
Integrating Metabolic, Perfusion, and Microstructural Parameters for Quantitative Neuroimaging in Rare Neurodegenerative Diseases: A Hybrid PET/MRI Approach
Strobel, J., Müller, H., Michelberger, L., Nosanova, A., Thaiss, W. M., Hæusler, K. G., Weishaupt, J. H., Kreiser, K., Beer, A. J., Beer, M., et al. (2026) · Diagnostics · doi:10.3390/diagnostics16132104
Self-citation
From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy
Harris, G. A., Barnhard, L., Brummet, J., & Diaz, K. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1893149

Positron emission tomography imaging of tau pathology in progressive supranuclear palsy
Coakeley, S., Cho, S. S., Koshimori, Y., Rusjan, P., Harris, M., Ghadery, C., Kim, J., Lang, A. E., Wilson, A. A., Houle, S., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16683695 · Cited by 55 · see citing works
Tau positron emission tomography in the Parkinson and Richardson subtypes of progressive supranuclear palsy
Alster, P., van Eimeren, T., & Madetko‐Alster, N. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107939 · Cited by 5 · see citing works
Neuroimaging in progressive supranuclear palsy
de Natale, E. R., Wilson, H., Politis, M., & Niccolini, F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821651-4.00004-x
Progressive Supranuclear Palsy
Pitman, J., & Ivanidze, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_30 · Cited by 5 · see citing works
18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy
Messerschmidt, K., Barthel, H., Brendel, M., Scherlach, C., Hoffmann, K., Rauchmann, B., Rullmann, M., MAREK, K. L., Villemagne, V. L., Rumpf, J., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262854 · Cited by 35 · see citing works

Authors: Strobel, J., Müller, H.-P., Ludolph, A. C., Beer, A. J., Sollmann, N., & Kassubek, J.
Affiliations: University Hospital Ulm (DE)
Universität Ulm (DE)
TUM Klinikum (DE)
Corresponding author: Strobel, Joachim
ORCID: Strobel, Joachim
Müller, Hans-Peter
Ludolph, Albert C.
Beer, Ambros J.
Sollmann, Nico
Kassubek, Jan
Venue: Cells
Publisher: MDPI AG
Published: 2023-12-06
Volume: 12
Issue: 24
Pages: 2776
ISSN: 2073-4409 (ISSN-L)
DOI: 10.3390/cells12242776
PMC: PMC10742083
OpenAlex: W4389387576
Cited by: 10
References: 159
Citations by year: 2026: 4 · 2025: 1 · 2024: 5
FWCI: 0.46
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Cells (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DZNE Pub (submittedVersion, cc-by)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords: progressive supranuclear palsy, hybrid imaging, PET/MRI, tau imaging, 18F-AV-1451, [11C]UCB-J, [11C]PK11195, synaptic density, Richardson's syndrome, diffusion MRI, cortical thickness, gray matter volume, structural connectivity, imaging biomarkers
MeSH terms: Humans, Supranuclear Palsy, Progressive, Reproducibility of Results, Biomarkers, Radiopharmaceuticals, Neurodegenerative Diseases, Multimodal Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

New Perspectives in Radiological and Radiopharmaceutical Hybrid Imaging in Progressive Supranuclear Palsy: A Systematic Review

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks